𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic factors for survival in patients treated in phase I clinical trials

✍ Scribed by Linda Janisch; Rosemarie Mick; Richard L. Schilsky; Nicholas J. Vogelzang; Sheila O'Brien; Michael Kuf; Mark J. Ratain


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
720 KB
Volume
74
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Background. Patients with advanced or metastatic cancer treated in Phase I clinical trials are considered to have a poor prognosis. Survival from first treatment in a Phase I trial was determined for 349 patients. Univariate and multivariate survival analyses were performed to determine whether potential prognostic factors and distinct risk groups could be identified.

Methods. Patients were identified retrospectively from a large data base of patients with advanced or metastatic cancer treated in Phase I clinical trials at the University of Chicago between February 1987 and October

1991.

Results. With a median follow-up of 29 months, 10% of patients were alive at the time of analysis. Twentynine percent were alive 1 year after the initiation of Phase I chemotherapy, and the median survival from first treatment in a Phase I study was 6.5 months. Multivariate analysis indicated that a better pretreatment performance status, a higher pretreatment serum albumin concentration, a lower pretreatment platelet count, no prior cisplatin chemotherapy, and a genitourinary or gynecologic cancer diagnosis were predictive of better survival. Three risk groups incorporating these five variables were identified, with median survivals of 12.7, 7.4, and 3.5 months for the good, intermediate, and poor risk groups, respectively .

Conclusion. Patients treated in Phase I clinical trials have a median survival of 6.5 months, even though some patients have been treated at early (subtoxic and potentially subtherapeutic) dose levels. The results of this study may allow the identification of patients who are From the Section of


πŸ“œ SIMILAR VOLUMES


Pretreatment prognostic factors for surv
✍ Joaquim Bellmunt; Joan Albanell; Luis Paz-Ares; Miguel A. Climent; Jose L. GonzΓ‘ πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 74 KB

## Background: New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplat

Analysis of prognostic factors in 568 pa
✍ Anna G. S. Muller; Jacobus A. van Zyl; Gina Joubert πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 439 KB

The Tygerberg Breast Clinic serves a heterogeneous population, and it is therefore possible to analyse prognostic factors influencing survival and to identify any possible differences between these groups. From 1978 to 1985, 568 breast cancer patients (52% white and 48% colored) were treated surgica